Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Olema aims to deploy $54M round to carve its niche in breast cancer

Danielle Golovin, Staff Writer
July 24, 2020 12:46 AM UTC

Olema’s plans for its oral selective estrogen receptor degrader attracted a crossover-laden syndicate to the San Francisco company’s $54 million series B round. Olema plans to take the therapy, which is administered daily, into a Phase I/II trial this year for breast cancer.

BVF Partners, Logos Capital and Janus Henderson Investors co-led the oversubscribed round, which closed on Wednesday and included new investors Cormorant Asset Management, RA Capital Management, Wellington Management Co., Surveyor Capital, Venrock Healthcare Capital Partners and Foresite Capital Management...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Astrazeneca plc

BVF Partners L.P.

Cormorant Asset Management

Foresite Capital Management LLC

Janus Henderson Investors

Logos Global Management LLC

Olema Pharmaceuticals Inc.